비교리스트

 카트 문의
시장보고서
상품코드
1513947

세계의 과활동 방광(OAB) 치료제 시장

Overactive Bladder (OAB) Therapeutics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 271 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

과활동 방광(OAB) 치료제 세계 시장은 2030년까지 15억 달러에 이를 전망

2023년에 12억 달러로 추정되는 과활동 방광(OAB) 치료제 세계 시장은 2030년에는 15억 달러에 이르고, 분석 기간 2023-2030년의 CAGR은 2.8%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 항콜린제는 CAGR 3.1%로 성장을 지속하고, 분석 기간 종료시에는 6억 1,470만 달러에 달할 것으로 예측됩니다. 신경 자극 치료 분야의 성장률은 분석 기간 동안 CAGR 2.4%로 추정됩니다.

미국 시장은 추정 3억 3,230만 달러, 중국은 CAGR 4.8%로 성장 예측

미국의 과활동 방광(OAB) 치료제 시장은 2023년 3억 3,230만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 4.8%로 성장을 지속하여 2030년에는 2억 9,070만 달러 규모에 이를 것으로 예측되고 있습니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.5%와 2.3%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 1.9%로 성장할 것으로 예측됩니다.

과활동 방광(OAB) 치료제 - 주요 동향 및 촉진요인

과활동 방광(OAB)은 방광벽의 근육의 갑작스런 불수의 수축을 특징으로 하는 비뇨기과 질환으로 긴급한 소변으로 이어집니다. 이 질병은 세계 수백만 명이 앓고 있으며 노인과 여성의 이환율이 높습니다. OAB는 삶의 질에 큰 영향을 미치며 사회적, 심리적, 신체적 고통을 유발합니다. OAB의 치료에는 항 무스카린 약물, β3 아드레날린 작용제, 보툴리눔툭신 주사와 같은 새로운 치료법 등 다양한 약물 요법이 있습니다. 이 치료는 방광의 근육을 이완시키고, 빈뇨를 줄이고, 증상을 효과적으로 관리하는 것을 목표로합니다. OAB 치료제 시장은 진화하고 있으며, 더 효과적이고 부작용이 적으며 환자의 컴플라이언스를 개선하는 약물 개발에 중점을 둔 연구가 진행되고 있습니다.

일부 동향은 OAB 치료제의 상황을 형성하고 있습니다. 중요한 동향 중 하나는 개인화된 의료로의 전환이며, 치료법을 개인의 유전적 프로파일 및 특정 증상에 맞추어 조정함으로써 치료 성적을 향상시킵니다. 경피 패치 및 서방형 제형과 같은 약물 전달 시스템의 혁신은 투여 횟수를 줄이고 부작용을 최소화함으로써 환자의 어드레싱을 향상시킵니다. 게다가 방광의 통제에 관여하는 여러 경로를 표적으로 하는 병용요법의 개발이 활발해지고 있어 보다 종합적인 증상관리를 제공합니다. 모바일 헬스 용도 및 웨어러블 디바이스를 포함한 디지털 헬스 기술은 OAB 관리에 점점 통합되고 있으며, 실시간 증상 추적 및 맞춤 치료 조정을 가능하게 하고 있습니다. 또한, 약물 치료에 반응하지 않는 환자에게 대체 치료 옵션을 제공하는 신경조절 기술과 같은 비-약물학적 개입에 대한 관심도 증가하고 있습니다.

OAB 치료제 시장의 성장은 여러 요인에 의해 야기됩니다. 약물 제제 및 약물 전달 시스템의 기술적 진보로 치료가 더 효과적이고 사용하기 쉽고 수요를 견인하고 있습니다. OAB에 걸리기 쉬운 세계 인구의 고령화가 대처할 수 있는 시장을 대폭 확대하고 있습니다. 교육 캠페인과 진단 도구의 개선에 힘입어 OAB의 인지도와 진단률의 향상이 치료 보급률의 상승으로 이어지고 있습니다. 또한 OAB의 위험인자인 당뇨병이나 비만 등 생활습관병의 유병률 상승이 시장 성장에 기여하고 있습니다. 제약기업은 뛰어난 효능과 안전성을 갖춘 신규 치료제를 도입하기 위해 연구개발에 많은 투자를 하고 있습니다. 디지털 건강 솔루션의 통합은 환자의 참여와 치료 요법에 대한 충고를 향상시킵니다. 게다가 특히 신흥 시장에서 유리한 상환정책과 헬스케어 인프라의 정비가 시장 확대를 뒷받침하고 있습니다. 이러한 요인들이 복합적으로 작용함에 따라 OAB 치료제 시장의 견조한 성장이 촉진되고, 환자의 더 나은 관리와 삶의 질 향상이 보장됩니다.

조사 대상 기업 예(총 34건)

  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.07.24

Global Overactive Bladder (OAB) Therapeutics Market to Reach US$1.5 Billion by 2030

The global market for Overactive Bladder (OAB) Therapeutics estimated at US$1.2 Billion in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Anticholinergics Therapy, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$614.7 Million by the end of the analysis period. Growth in the Neurostimulation Therapy segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$332.3 Million While China is Forecast to Grow at 4.8% CAGR

The Overactive Bladder (OAB) Therapeutics market in the U.S. is estimated at US$332.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$290.7 Million by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Overactive Bladder (OAB) Therapeutics - Key Trends and Drivers

Overactive Bladder (OAB) is a prevalent urological condition characterized by a sudden, involuntary contraction of the muscle in the wall of the urinary bladder, leading to an urgent need to urinate. This condition affects millions of people worldwide, with a higher incidence among the elderly and women. OAB significantly impacts the quality of life, causing social, psychological, and physical distress. Therapeutics for OAB include a range of pharmacological treatments such as antimuscarinics, beta-3 adrenergic agonists, and newer modalities like botulinum toxin injections. These treatments aim to relax the bladder muscle, reduce urinary frequency, and manage symptoms effectively. The market for OAB therapeutics is evolving, with ongoing research focused on developing drugs with better efficacy, fewer side effects, and improved patient compliance.

Several trends are shaping the landscape of OAB therapeutics. One significant trend is the shift towards personalized medicine, where treatments are tailored to the individual’s genetic profile and specific symptoms, thereby enhancing treatment outcomes. Innovations in drug delivery systems, such as transdermal patches and extended-release formulations, are improving patient adherence by reducing the frequency of dosing and minimizing side effects. Additionally, the development of combination therapies that target multiple pathways involved in bladder control is gaining traction, offering more comprehensive symptom management. Digital health technologies, including mobile health applications and wearable devices, are increasingly being integrated into OAB management, enabling real-time symptom tracking and personalized treatment adjustments. Furthermore, there is growing interest in non-pharmacological interventions, such as neuromodulation techniques, which offer alternative treatment options for patients who do not respond well to medication.

The growth in the OAB therapeutics market is driven by several factors. Technological advancements in drug formulation and delivery systems are making treatments more effective and user-friendly, thereby driving demand. The aging global population, which is more susceptible to OAB, is significantly expanding the addressable market. Increased awareness and diagnosis rates of OAB, fueled by educational campaigns and improved diagnostic tools, are leading to higher treatment adoption. Additionally, the rising prevalence of lifestyle diseases such as diabetes and obesity, which are risk factors for OAB, is contributing to market growth. Pharmaceutical companies are investing heavily in research and development to introduce novel therapeutics with superior efficacy and safety profiles. The integration of digital health solutions is enhancing patient engagement and adherence to treatment regimens. Furthermore, favorable reimbursement policies and healthcare infrastructure improvements, particularly in emerging markets, are supporting market expansion. The collective impact of these factors is fostering robust growth in the OAB therapeutics market, ensuring better management and improved quality of life for affected individuals.

Select Competitors (Total 34 Featured) -

  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Overactive Bladder (OAB) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Aging Global Population Expands Addressable Market Opportunity for OAB Therapeutics
    • Innovations in Drug Delivery Systems Propel Growth in OAB Treatment Solutions
    • Personalized Medicine Throws the Spotlight on Tailored OAB Therapeutic Approaches
    • Advances in Neuromodulation Techniques Strengthen Business Case for Non-Pharmacological Interventions
    • Increased Awareness and Diagnosis Rates Drive Adoption of OAB Treatments
    • Rising Prevalence of Lifestyle Diseases Generates Demand for OAB Therapeutics
    • Integration of Digital Health Technologies Accelerates Demand for Real-Time Symptom Management
    • Development of Combination Therapies Enhance Comprehensive Symptom Control
    • Improved Diagnostic Tools Enhanced Early Detection and Treatment
    • Technological Advancements in Extended-Release Formulations Sustain Growth in OAB Market
    • Consumer Preference for Non-Invasive Treatments Expands Market for Alternative Therapies
    • Economic Burden of Untreated OAB Fuels Demand for Effective Management Solutions
    • Impact of Telemedicine Services on Enhancing Patient Access and Treatment Compliance
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Overactive Bladder (OAB) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Neurostimulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Neurostimulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Neurostimulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Botox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Botox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Botox by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Mirabegron by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Mirabegron by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Mirabegron by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • JAPAN
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • CHINA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • EUROPE
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • FRANCE
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • GERMANY
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • INDIA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • AFRICA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제